Endothelin Role In COronary Microcirculation (NCT07670091) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Endothelin Role In COronary Microcirculation
United Kingdom45 participantsStarted 2023-07-01
Plain-language summary
Coronary microvascular dysfunction is an important cause of angina in patients who do not have significant blockages in the major coronary arteries. Previous studies suggest that endothelin-1, a naturally occurring substance that causes blood vessel constriction, may contribute to abnormalities in the coronary microcirculation.
The ERICOM study aims to investigate whether treatment with bosentan, an endothelin receptor antagonist, can improve coronary microvascular function in patients with angina and evidence of coronary microvascular dysfunction. Participants undergo cardiovascular magnetic resonance (CMR) imaging before and after treatment, and some participants also undergo invasive coronary physiological assessment.
The results of this study may improve understanding of the role of endothelin-1 in coronary microvascular dysfunction and help identify new treatment strategies for patients with angina and non-obstructive coronary artery disease.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Clinical diagnosis of symptomatic angina, defined as the presence of substernal chest pain or discomfort provoked by exertion or emotional stress and relieved by rest and/or glyceryl trinitrate (nitroglycerin).
. Age 18 years or older.
. Able and willing to provide written informed consent.
. Able and willing to adhere to study procedures and follow-up requirements.
Exclusion criteria
. Symptoms consistent with unstable angina, including:
. Angina at rest lasting more than 20 minutes.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Myocardial Perfusion Reserve Index (MPRI) following Bosentan treatment
Timeframe: Baseline and 4 weeks
Trial details
NCT IDNCT07670091
SponsorLiverpool University Hospitals NHS Foundation Trust
. Angina increasing in frequency, duration, or occurring at a lower threshold.
. Angina occurring following a recent myocardial infarction.
. Known significant coronary artery disease, defined as previous investigations demonstrating greater than 50% epicardial coronary artery stenosis.
. Uncontrolled hypertension, defined as clinic blood pressure greater than 140/90 mmHg despite treatment with three or more antihypertensive medications.